Luis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1.
uis A. Diaz, Jr, MD, associate professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discovered that patients with high mutational burden with mismatched repair responded well to checkpoint inhibition of PD1. For colon cancer and perhaps for additional cancers such as pancreatic, lung, and ovarian, Dr Diaz predicts that mismatched repair testing will change the course of cancer treatment in the coming years.
L
“My suspicion is that this will become standard of care in the near future for colon cancer. And that will demand that mismatched repair testing be a part of the standard of care for those patients,” Dr Diaz said. “And I suspect that up front, when you get diagnosed with advanced colon cancer, you’re going to get mismatched repair testing.”
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center is now in collaboration with Merck, which Dr Diaz said is in the beginning stages of opening 2 new studies focused on patients who failed all therapy and on patients who are newly diagnosed in an effort to compare which standard of care works more effectively.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More